This page shows the latest anti-B-cell maturation antigen news and features for those working in and with pharma, biotech and healthcare.
The European Commission (EC) has approved Bristol Myers Squibb/bluebird bio’s first-in-class anti-B-cell maturation antigen (BCMA) CAR T cell therapy Abecma (idecabtagene vicleucel) for patients with ... Abecma is the first CAR T cell therapy that is
GSK2857916 is an anti-B-cell maturation antigen (BCMA) antibody-drug conjugate, and results from the DREAMM-1 first-in-human open label trial showed that 60% of patients achieved an ... Another is DREAMM-2, which looks at multiple myeloma patients who
New studies of chimeric antigen receptor T cell (CAR-T) immunotherapy - which was named by ASCO as the advance of the year in its annual report published in January - will be ... On the first day of the show, Celgene and Bluebird Bio will be reporting
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
No results were found
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....